Patents by Inventor Katie Olson
Katie Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230174641Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: ApplicationFiled: June 27, 2022Publication date: June 8, 2023Inventors: Andrew Lawrence FELDHAUS, Leon GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katie Olson ANDERSON, Ethan Wayne OJALA, Pei FAN, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Jeffrey T.L. SMITH, John LATHAM
-
Patent number: 11427631Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: February 3, 2020Date of Patent: August 30, 2022Assignee: H. LUNDBECK A/SInventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Publication number: 20220073606Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: ApplicationFiled: August 9, 2021Publication date: March 10, 2022Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T.L. Smith, John Latham
-
Patent number: 11117960Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: December 9, 2019Date of Patent: September 14, 2021Assignee: H. LUNDBECK A/SInventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Patent number: 11111289Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: January 15, 2019Date of Patent: September 7, 2021Assignee: H. LUNDBECK A/SInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20210047391Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: January 13, 2020Publication date: February 18, 2021Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20200317772Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: ApplicationFiled: February 3, 2020Publication date: October 8, 2020Inventors: Andrew Lawrence FELDHAUS, Leon GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katie Olson ANDERSON, Ethan Wayne OJALA, Pei FAN, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Jeffrey T.L. SMITH, John LATHAM
-
Publication number: 20200172611Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: ApplicationFiled: December 9, 2019Publication date: June 4, 2020Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T.L. Smith, John Latham
-
Patent number: 10550180Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: June 5, 2017Date of Patent: February 4, 2020Assignee: ALDERBIO HOLDINGS LLCInventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Patent number: 10544214Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: August 13, 2018Date of Patent: January 28, 2020Assignee: ALDERBIO HOLDINGS LLCInventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Patent number: 10533048Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: August 30, 2018Date of Patent: January 14, 2020Assignee: ALDERBIO HOLDINGS LLCInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20190389968Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.Type: ApplicationFiled: March 6, 2019Publication date: December 26, 2019Inventors: Andrew Lawrence FELDHAUS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Ethan Wayne OJALA, Brian Robert KOVACEVICH, Katie Olson ANDERSON, Pei FAN, Jens BILLGREN, Erica Ann STEWART, Corinne C. AKATSUKA, Patricia Dianne MCNEILL, Danielle Marie MITCHELL, Dan Scott ALLISON, John A. LATHAM
-
Publication number: 20190211085Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: January 15, 2019Publication date: July 11, 2019Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Patent number: 10259885Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.Type: GrantFiled: December 22, 2015Date of Patent: April 16, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan Wayne Ojala, Brian Robert Kovacevich, Katie Olson Anderson, Pei Fan, Jens Billgren, Erica Ann Stewart, Corinne C. Akatsuka, Patricia Dianne McNeill, Danielle Marie Mitchell, Daniel Scott Allison, John A. Latham
-
Publication number: 20190092842Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: August 30, 2018Publication date: March 28, 2019Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20190083665Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: ApplicationFiled: October 1, 2018Publication date: March 21, 2019Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall C. Schatzman
-
Publication number: 20190085073Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: ApplicationFiled: August 13, 2018Publication date: March 21, 2019Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T.L. Smith, John Latham
-
Patent number: 10214582Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: February 9, 2018Date of Patent: February 26, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Patent number: 10208112Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: February 9, 2018Date of Patent: February 19, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Patent number: 10189895Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: GrantFiled: February 9, 2018Date of Patent: January 29, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis